

CT-Plaque Activity

A new marker of heart attack risk



Sander Bangma, CEO

Navier Medical Limited

Bioshares Biotech Summit
7 & 8 August 2025



Disclosure and Disclaimer

This presentation, together with any information communicated by Navier Medical Ltd (“Navier” or “the Company”), in any presentation or discussion relating to this document (collectively, “Information”) is confidential, and has been prepared by the Company and on the condition that it is for the exclusive information and use of the recipient. The Information is proprietary to Navier and may not be disclosed to any third party or used for any other purpose without the prior written consent of the Company. Except as otherwise expressly stated, Navier has not authorised any person to give any information or make any representation which is not contained in this document. Any such information or representation not contained in this presentation must not be relied upon as having been authorised by, or on behalf of, Navier.

This presentation contains forward-looking statements concerning Navier. Forward-looking statements are not statements of historical fact and actual events and results may differ materially from those described in the forward-looking statements as a result of a variety of risks, uncertainties and other factors. Forward-looking statements are inherently subject to business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause the Company’s actual results to differ materially from those expressed or implied in any forward-looking information provided by the Company, or on behalf of, the Company. Forward looking statements in this document are based on the company’s beliefs, opinions and estimates of Navier Medical Ltd as of the dates the forward-looking statements are made, and no obligation is assumed to update forward looking statements if these beliefs, opinions and estimates should change or to reflect other future developments. There is NO guarantee of future performance, Including that Navier will achieve its stated objectives / milestones, that its forecasts will be met or that forward looking statements will be realised - actual results and future outcomes will in all likelihood differ from those outlined herein.

This presentation is not a recommendation, offer or invitation to subscribe for or purchase Navier securities. This presentation is not exhaustive of all of the information a potential investor or their professional advisers would require. This presentation does NOT constitute a “Prospectus” or a “Disclosure Document” (as defined in the Corporations Act 2001 (Cth)).

To the maximum extent permitted at law, Navier and all of its representatives, directors, partners, employees or professional advisers exclude all direct and indirect liability arising out of or in connection with any use or reliance of the information contained or described within this presentation. Other than to the extent required by law (and only to that extent), Navier and its representatives and advisers do not make any representation or give any assurance, guarantee or warranty (express or implied) as to, nor assume any responsibility or liability for, the authenticity, origin, validity, accuracy, suitability or completeness of, or any errors in or omissions from, any information, statement or opinion contained in this document or any accompanying, previous or subsequent material or presentation.

Develop & commercialise
medical image analysis solutions
to improve assessment of
cardiovascular disease

Incorporated **2021**



First-generation SaMD
Mosaic V1 cleared by FDA

2025



WA Innovator of the Year

2021



Australian
Patients
Association

Most Outstanding Patient Innovation


2022



Selected for
ANDHealth+ program

2024

Coronary artery disease is the world's biggest killer at >9M deaths per year - the current treatment pathway fails patients



* Adopted in clinical guidelines worldwide: USA / EU / UK




*To improve prediction of future adverse cardiovascular events, cardiac CT needs to identify **local biological processes that drive disease and events**...*

– Prof Keith Channon⁴ (Oxford University)

Plaque activity is a **biological process** driving disease and **causing heart attacks**


Current standard of care reads the **visible markers** on cardiac CT



PLAQUE ACTIVITY
Not visible on CT



REQUIRES A NAF-PET SCAN



7x higher risk of a heart attack
if you have plaque activity^{1,2}



New early warning flag to predict heart attacks



Can be reduced by medical therapy³




REVEAL PLAQUE ACTIVITY ON CT




Mosaic V2 – our solution: SaaS + Plaque Activity

AI-driven software revealing plaque activity on cardiac CT **without a NaF-PET scan**



The market size and opportunity is growing fast...



Commercial strategy



Target the US first as reimbursement codes exist – phased approach

1 Mosaic V1



Initial platform for pilot studies,
product feedback & early partnering

- ✓ Active discussion with selected hospitals & radiology providers
- ✓ Early engagement & workflow integration

2 Mosaic Next-Gen: SaaS + Plaque Activity

- ✓ Initially self-commercialise via SaaS¹;
seek partnerships (e.g. CT manufacturers & PACS vendors)
- ✓ Target key customers in both public and private practices;
develop customer case studies / success stories
- ✓ Leverage attractive reimbursement via fee-sharing with clinics;
turning their CT scanners into revenue streams

3 Expand target markets & product portfolio

- ✓ EU, Australia & Others
- ✓ CT-FFR & Plaque Activity in stroke



Expert team with decades of experience in tech, engineering, cardiology, and commercialisation



Otto Buttula
Chair

Extensive experience and success in investment, funds management and Info/Bio/Med-Tech
Chair of Rhythm Biosciences (ASX: RHY)
Built IWL Ltd (ASX: IWL) prior to takeover by CommBank for \$373M in 2007



Sander Bangma
MD & CEO

>15 yrs in medical software devices, including obtaining FDA, TGA & CE
Led Resonance Health Ltd (ASX: RHT) as GM & COO
Led product strategy & development for Moodle; global EdTech software platform with 300M+ users



A/Prof Barry Doyle
Founder, ED & CTO

>19 yrs in cardiovascular bioengineering, devices & clinical research
Led Cardiovascular Science & Vascular Engineering at the Harry Perkins Institute of Medical Research
Adj. A/Prof of Biomedical Eng. at University of Western Australia (Top 100 Uni)



Aastha Chaudhary
QA & RA

>15 yrs experience in Quality Assurance & Regulatory Affairs
Extensive experience in SaMD, including AI/ML based devices in USA, EU, and AU.
ex-HeartFlow and Cleerly



Dr Lachlan Kelsey
Head of Engineering

>10 yrs in computer-aided engineering and biomedical engineering
Co-developed methods behind Mosaic during his PhD at UWA/Perkins (with Barry Doyle and cardiologist Prof Carl Schultz)



Dr Jonathan Tapley
Medical Image Eng

Junior Doctor at RPH; degrees in Physics and Medicine
Worked with Barry & Lachlan since 2018
AI/ML engineer

Advisory Board



Prof David Newby

Pioneer of plaque activity imaging method with PET
International leader in cardiology, imaging and clinical trials
BHF Duke of Edinburgh Chair of Cardiology at Edinburgh University
Led major clinical trials that changed cardiology clinical practice (e.g. SCOT-HEART)



Nicholas Wharton

President & founder of LightSource Research: consultancy for medical device AI and commercialisation
Co-founder & former SVP of Medical Metrics: leading imaging CRO for medical device trials
Network of clinicians, service providers, and reimbursement experts
Based in Houston, USA (Texas Medical Center)



Prof Derek Chew

International leader in cardiology, digital tech and clinical trials
Professor of Cardiology at Monash University
Director of Health Informatics Research at Victorian Heart Institute (VHI)
Director at Monash Heart and VHI (Victorian Heart Hospital)



Team is expanding



Thank you

Navier Medical Ltd
ACN 651 654 858

Contact
Sander Bangma – CEO
E sander.bangma@naviermedical.com